Current Report Filing (8-k)
February 21 2019 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT Pursuant to
ection 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date
of earliest event reported): February 21, 2019
STAAR
Surgical Company
(Exact Name of Registrant
as Specified in Charter)
Delaware
|
0-11634
|
95-3797439
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
1911 Walker Ave., Monrovia, California
|
91016
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code
626-303-7902
Not Applicable
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 7.01 Regulation FD Disclosure.
On February 21, 2019, STAAR Surgical Company
(the “Company”) published a press release reporting its financial results for the quarter and fiscal year ended December
28, 2018, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
This
information and the information contained in the press release shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information
in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the
Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation
language in the filing unless specifically stated so therein
.
Item 9.01 Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
|
|
February 21, 2019
|
By:
|
/s/ Caren Mason
|
|
|
|
Caren Mason
|
|
|
|
President and Chief Executive Officer
|
|
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2024 to Sep 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2023 to Sep 2024